Related Experiment Video
Updated: Aug 20, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Charge modifications of graphene oxide enhance the inhibitory effect on insulin amyloid fibrillation based on
Xin Sun1, Chunyan Yang1, Wei Liu1
1School of Chemical Engineering and Technology, Hebei University of Technology, No. 8 Guangrong Road, DingziGu, Hongqiao District, Tianjin 300130, China.
Abstract:
Graphene oxide (GO) is a biocompatible nanomaterial that has an inhibitory effect on insulin amyloid fibrillation. In order to enhance the inhibitory effect of GO and explore the rules of electrostatic interactions on the inhibitory effect, carboxyl group, PEI and PEG were coupled to the GO nanoplatelet surface to prepare inhibitors of different surface electrical properties. The effects of surface electrical properties of inhibitors on insulin fibrillation were investigated. The results showed that GO, carboxyl group modified GO (GO-COOH), PEI modified GO (GO-PEI), and PEG modified GO (GO-PEG) inhibited insulin fibrillation in a dose-dependent manner. Compared with GO, positive charge-modified GO-PEI and negative charge-modified GO-COOH enhanced the inhibitory effect, while uncharged polymer-modified GO-PEG weakened the inhibitory effect. The inhibitory effect of the inhibitors increased with the increase of surface charge density. The difference in inhibitory effect between GO-PEI and GO-COOH was due to the different electrostatic interactions between inhibitors and insulin, and the different inhibition mechanisms. In addition, inhibitors mainly interact with insulin during the nucleation phase to hinder insulin fibrillation. The charge modifications of graphene oxide enhanced the inhibitory effect on insulin fibrillation based on electrostatic interactions, which will provide new thoughts for the development of anti-amyloid fibrillation drugs.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Oral Hypoglycemic Agents: Biguanides and Glitazones

